Fortress Biotech Inc (FBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fortress Biotech Inc (FBIO) has a cash flow conversion efficiency ratio of -0.202x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.54 Million) by net assets ($62.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fortress Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Fortress Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read FBIO current and long-term liabilities for a breakdown of total debt and financial obligations.
Fortress Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fortress Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hipages Group Holdings Ltd
AU:HPG
|
0.304x |
|
Westwater Resources Inc
NYSE MKT:WWR
|
-0.011x |
|
Transat AT Inc
TO:TRZ
|
0.178x |
|
American Tungsten & Antimony Ltd
AU:AT4
|
-0.417x |
|
Tuniu Corporation
F:0TUA
|
N/A |
|
Suominen Oyj
HE:SUY1V
|
-0.099x |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
-0.179x |
|
Seoul Auction Co. Ltd
KQ:063170
|
0.048x |
Annual Cash Flow Conversion Efficiency for Fortress Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Fortress Biotech Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Fortress Biotech Inc (FBIO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $62.18 Million | $-65.78 Million | -1.058x | -102.17% |
| 2024-12-31 | $-1.64 Million | $-80.19 Million | 48.778x | +160.37% |
| 2023-12-31 | $1.59 Million | $-128.22 Million | -80.797x | -2152.98% |
| 2022-12-31 | $50.02 Million | $-179.40 Million | -3.586x | -595.08% |
| 2021-12-31 | $225.88 Million | $-116.54 Million | -0.516x | -21.46% |
| 2020-12-31 | $197.00 Million | $-83.68 Million | -0.425x | +67.55% |
| 2019-12-31 | $72.53 Million | $-94.96 Million | -1.309x | +73.85% |
| 2018-12-31 | $19.74 Million | $-98.85 Million | -5.007x | -606.22% |
| 2017-12-31 | $120.50 Million | $-85.43 Million | -0.709x | -28.39% |
| 2016-12-31 | $82.97 Million | $-45.81 Million | -0.552x | -128.35% |
| 2015-12-31 | $84.27 Million | $-20.38 Million | -0.242x | -4.40% |
| 2014-12-31 | $70.52 Million | $-16.33 Million | -0.232x | +36.50% |
| 2013-12-31 | $81.28 Million | $-29.65 Million | -0.365x | +65.35% |
| 2012-12-31 | $22.03 Million | $-23.19 Million | -1.053x | -83.89% |
| 2011-12-31 | $19.13 Million | $-10.95 Million | -0.572x | -34.92% |
| 2010-12-31 | $13.38 Million | $-5.68 Million | -0.424x | -282.10% |
| 2009-12-31 | $-10.09 Million | $-2.35 Million | 0.233x | -- |
About Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe reca… Read more